San Francisco’s Syapse has partnered with Roche to make precision medicine a reality for more cancer patients and their healthcare providers.
The two companies will work jointly to develop software products and analytics solutions that empower healthcare providers with the tools and insights they need to practice precision medicine at scale.
Roche will fund the development of these products, which will benefit oncologists and their care team, health systems, and ecosystem stakeholders including payers.
Building on its Platform, Syapse will develop and deploy these new products to the precision medicine ecosystem, beginning with its existing healthcare provider network.
“Precision medicine is already improving cancer care, and Syapse is empowering healthcare providers with the tools they need to deliver the best possible care,” said Ken Tarkoff, CEO of Syapse.
“By working together, Syapse and Roche can make this vision of precision medicine a reality faster than either of us could alone.”
Initially, Syapse and Roche will focus on four product programs: developing a “learning health system” of real-world evidence that enables physicians to make better care decisions; bringing cancer care into the “value-based” era by better understanding the health economics impact and patient outcomes of precision medicine; advancing electronic patient-reported outcomes to understand precision medicine’s effect on health-related quality of life; and accelerating clinical trial enrolment by matching patients to precision trials at the point of care.
Roche and Syapse will also collaborate on automated methods for measuring real-world outcomes, and will explore additional areas of collaboration with the potential to bring precision medicine and improve care for more patients.